fianlimab
Sponsor Regeneron Pharmaceuticals, INC. · listed as REGN
fianlimab is a drug asset sponsored by Regeneron Pharmaceuticals, INC., listed as REGN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Mar 22, 2027 (day precision, medium confidence), tied to trial NCT06246916. That trial is in Phase 3 and currently recruiting, studying Melanoma. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for fianlimab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-03-22 | READOUT | medium | NCT06246916 |
| 2027-09-28 | READOUT | medium | NCT05785767 |
Trials for fianlimab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05352672 | Phase 3 | Active, not recruiting | 2026-03-12 | Experimental | Regeneron Pharmaceuticals | Melanoma |
| NCT05608291 | Phase 3 | Active, not recruiting | 2026-07-27 | Experimental | Regeneron Pharmaceuticals | Melanoma |
| NCT06246916 catalyst | Phase 3 | Recruiting | 2027-03-22 | Experimental | Regeneron Pharmaceuticals | Melanoma |
| NCT05785767 catalyst | Phase 2/3 | Active, not recruiting | 2027-09-28 | Experimental | Regeneron Pharmaceuticals | Advanced Non-Small Cell Lung Cancer |
| NCT05800015 | Phase 2/3 | Active, not recruiting | 2030-01-16 | Experimental | Regeneron Pharmaceuticals | Non-small Cell Lung Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More REGN catalysts